lymphocyte-activation gene 3 + interleukin-15

**lymphocyte-activation gene 3 + interleukin-15** refers to an experimental **combination immunocytokine concept** rather than a single approved drug: a LAG-3-targeted IL-15 agonist format in which an antigen-binding domain directed at **lymphocyte-activation gene 3** is fused with or paired to an **IL-15 or IL-15/IL-15Ralpha** cytokine module. The intended mechanism is to deliver IL-15 costimulatory signaling to **LAG-3-expressing activated or exhausted lymphocytes**, thereby expanding and activating cytotoxic lymphocytes while using LAG-3 binding for selective immune-cell targeting. Published evidence appears to be preclinical and patent/AACR abstract based, describing heterodimeric Fc-fusion or related immunocytokine designs for oncology and immunotherapy applications rather than a clearly established clinical-stage named asset.

Other names

LAG-3 x IL-15LAG3 x IL-15LAG 3 x IL-15LAG3 x IL15LAG-3 x IL15LAG 3 x IL15LAG-3 targeted IL15/IL15Ralpha fusion protein